苯基(哌啶-2-基)甲酮盐酸盐 | 138371-65-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 苯基(哌啶-2-基)甲酮盐酸盐
• 中文别名: 苯基-2-哌啶基甲酮盐酸盐
• 英文名称: 2-benzoylpiperidine hydrochloride
• 英文别名: phenyl(2-piperidinyl)methanone hydrochloride；phenyl(piperidin-2-yl)methanone hydrochloride；phenyl(piperidin-2-yl)methanone;hydrochloride
• CAS: 138371-65-0
• 化学式: C₁₂H₁₅NO*ClH
• 分子量: 225.718
• InChiKey: OSLHXWHFSJMVQY-UHFFFAOYSA-N

物化性质

• 熔点：
  >215°C (dec.)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.43
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Benzoylpiperidine hydrochloride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Benzoylpiperidine hydrochloride
CAS number: 138371-65-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H16ClNO
Molecular weight: 225.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  苯基(哌啶-2-基)甲酮盐酸盐 生成 (2R*,1'S*)-1-amino-2-(1'-hydroxybenzyl)piperidine
  参考文献：
  名称：

  The Conformational Behaviour of 4,4a,5,6,7,8-Hexahydropyrido[1,2-d][1,3,4]oxadiazine Derivatives Studied by NMR Spectroscopy and Molecular Mechanics.

  摘要：

  The diastereomers (1'R*,2R*)- and (1'S*,2R*)-1-amino-2-(1'-hydroxypiperidinebenzyl) and 1-amino-2-(1-hydroxy-1,1-diphenylmethyl) have been synthesized and transformed into the corresponding 4,4a,5,6,7,8-hexahydropyrido[1,2-d][1,3,4]oxadiazines Similarly to the unsubstituted parent compound 2-phenylhexahydropyrido [1,2-d][1,3,3] oxadiazine, both the (4R*,4aR*)- and the (4S*,4aR*)-2,4-diphenylhexahydropyrido [1,2-d][1,3,4]oxadiazines were found to be predominantly in the trans-annellated conformation. This was concluded from low temperature NMR measurements, the chemical shift differences of the methylene protons adjacent to the bridged nitrogen, or the Delta H degrees values derived from ab initio calculations. In 2,4,4-triphenylhexahydropyrido[1,2-d][1,3,4]oxadiazine the conformational preference was switched to a slight predominance of the cis N-in conformation (53%). The conformational preference in the solid state for the (4R*,4aR*)- and the (4S*,4aR*)-2,4-diphenylhexahydropyrido[ 1,2-d][ 1,3,4]oxadiazines was the same as in solution. The N-15 chemical shifts of the bridgehead nitrogens were found to correlate to some extent with the conformational preference, while no correlation was observed between the geminal coupling constant of the methylene protons adjacent to the bridgehead and the adopted ring annellation.

  DOI：

  10.3891/acta.chem.scand.53-0213
• 作为产物：
  描述：

  (2-氧代-2-苯乙基)-氨基甲酸叔丁酯 在 盐酸 、 sodium hydride 作用下， 以 甲醇 为溶剂， 反应 2.25h， 生成 苯基(哌啶-2-基)甲酮盐酸盐
  参考文献：
  名称：

  α-叔丁氧基羰基氨基酮烯醇阴离子的烷基化。α-烷基-α-氨基酮、2-酰基吡咯烷和2-酰基哌啶的有用合成

  摘要：

  α-烷基-α-氨基酮 5 和环状 α-氨基酮 7 的多功能合成基于选择性单-α-烷基化和 C(α)、N-环烷基化 α-叔丁氧基羰基氨基酮 2 和亚基。. .

  DOI：

  10.1139/v91-298

文献信息

• C–H/C–C Functionalization Approach to N-Fused Heterocycles from Saturated Azacycles
  作者：Jin Su Ham、Bohyun Park、Mina Son、Jose B. Roque、Justin Jurczyk、Charles S. Yeung、Mu-Hyun Baik、Richmond Sarpong

  DOI：10.1021/jacs.0c04278

  日期：2020.7.29

  Herein, we report the synthesis of substituted indolizidines and related N-fused bicycles from simple saturated cyclic amines through sequential C-H and C-C bond functionalizations. Inspired by the Norrish-Yang Type II reaction, C-H functionalization of azacycles is achieved by forming α-hydroxy-β-lactams from precursor α-ketoamide derivatives under mild, visible light conditions. Selective cleavage

  在此，我们报道了通过连续的 CH 和 CC 键功能化，从简单的饱和环胺合成取代的吲哚里西啶和相关的 N-稠合双环。受 Norrish-Yang II 型反应的启发，氮杂环化合物的 CH 官能化是通过在温和的可见光条件下由前体 α-酮酰胺衍生物形成 α-羟基-β-内酰胺来实现的。使用Rh复合物选择性裂解α-羟基-β-内酰胺中的远端C(sp2)--C(sp3)键产生α-酰基中间体，该中间体经历连续的Rh催化脱羰基化，1,4加成到亲电子试剂和羟醛环化，得到包括吲哚里西啶的 N-稠合自行车。计算研究为观察到的 CC 裂解的位置选择性提供了机制上的见解，这在很大程度上取决于与膦配体的 Rh 反式结合的基团。
• Synthetic Cathinone Analogues Structurally Related to the Central Stimulant Methylphenidate as Dopamine Reuptake Inhibitors
  作者：Barkha J. Yadav-Samudrala、Jose M. Eltit、Richard A. Glennon

  DOI：10.1021/acschemneuro.9b00284

  日期：2019.9.18

  well-defined. Hence, available tMP literature might assist in understanding the SAR of synthetic cathinones, about which less is known. In the present study, we synthesized and examined eight 2-benzoylpiperidine analogues (4, 6-12) to determine if tMP SAR might be applicable to cathinone SAR. The benzoylpiperidine analogues were evaluated in a competition assay using live-cell imaging against APP+ in HEK293

  合成的卡西酮主要是滥用刺激性药物，它们在单胺转运蛋白（例如，多巴胺转运蛋白或DAT）上充当释放剂或再摄取抑制剂。在过去的几年中，> 150种新型合成卡西酮的出现引起了医学界和执法界的极大关注。在临床上用于治疗注意力缺陷多动障碍和发作性睡病的苏氨酸-哌醋甲酯（tMP）也是一种DAT再摄取抑制剂。tMP在某种程度上类似于滥用的卡西酮兴奋剂，并且tMP的构效关系（SAR）已得到明确定义。因此，可用的tMP文献可能有助于理解合成卡西酮的SAR，对此知之甚少。在本研究中，我们合成并检查了8种2-苯甲酰基哌啶类似物（4，6-12）确定tMP SAR是否适用于卡西酮SAR。苯甲酰基哌啶类似物在竞争测定中使用针对APP +的活细胞成像在稳定表达hDAT的HEK293细胞中以及在共表达DAT和电压门控Ca2 +通道的细胞中进行了评估。发现所有化合物都是DAT再摄取抑制剂，并且苯甲酰哌啶的效价与tMP结合数据之间具有显着相关性（r
• Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
  申请人：Seko Takuya

  公开号：US20050085476A1

  公开（公告）日：2005-04-21

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  公式(I)所代表的融合吡啶嗪衍生物或其药学上可接受的盐（其中每个符号的含义如说明书所定义）。由于抑制多聚腺苷酸核苷酸聚合酶，公式（I）所代表的化合物可用作各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等处）、炎症性疾病（炎症性肠病、多发性硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等）、糖尿病、休克、头部创伤、肾功能衰竭、高痛感等的预防和/或治疗剂。此外，这些化合物可用作抗逆转录病毒剂（HIV等）、癌症治疗敏感剂和免疫抑制剂。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Seko Takuya

  公开号：US20080261947A1

  公开（公告）日：2008-10-23

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式（I）所表示的融合吡嗪衍生物或其药学上可接受的盐（其中每个符号的含义如规范中所定义）。由于抑制了聚(ADP-核糖)聚合酶，式（I）所表示的化合物可用作预防和/或治疗各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等部位），炎症性疾病（炎症性肠病、多发性硬化症、关节炎等），神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等），糖尿病、休克、头部创伤、肾功能衰竭、高痛感等。此外，这些化合物还可用作抗逆转录病毒剂（HIV等）、治疗癌症的增敏剂和免疫抑制剂。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1477175A1

  公开（公告）日：2004-11-17

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  由式（I）代表的融合哒嗪衍生物或其药学上可接受的盐（其中各符号的含义如说明书中所定义）。 由于能抑制多（ADP-核糖）聚合酶，式（I）代表的化合物可作为各种缺血性疾病（脑、脊髓、心脏、消化道、骨骼肌、视网膜等）、炎症性疾病（炎症性肠病）的预防和/或治疗药物。炎症性疾病（炎症性肠病、多发性脑硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌肉萎缩症、腰椎管狭窄症等）、糖尿病、休克、头部创伤、肾功能衰竭、痛觉减退等。此外，这些化合物还可用作抗逆转录病毒（HIV 等）的药物、治疗癌症的增敏剂和免疫抑制剂。